Vasoactive Intestinal Peptide — The Complete History

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

The Legacy

A Global Healing Tool Emerges

Today, VIP represents a unique story in peptide medicine.

Key Moment

It was discovered half a century ago and is already being used to help patients in some countries.

Today, VIP represents a unique story in peptide medicine. It was discovered half a century ago and is already being used to help patients in some countries. In the United States, more advanced trials are underway to expand its approved uses. Researchers continue discovering new potential applications. Some are testing VIP for systemic inflammation. Others are exploring its role in protecting nerve cells. Still others are investigating whether VIP might help heart failure patients. The peptide that was first found in pig lungs has become a symbol of how fundamental research can lead to real healing. Dr. Said's legacy is that a simple curiosity about how lungs work has become a medical tool that helps patients breathe and live better.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

VIP is a 28-amino acid neuropeptide that requires exact sequencing and proper disulfide bonding to maintain receptor affinity for VPAC1 and VPAC2, making small-batch synthesis with per-residue quality control the only reliable production method.
Purity percentages alone don't predict VIP function. Sequence verification by HPLC-MS and bioactivity testing in cAMP-stimulation assays are required to confirm that synthesized VIP adopts the correct bioactive conformation.
VIP degrades rapidly above −20°C in lyophilized form and above 2–8°C once reconstituted, with oxidation of methionine-17 and histidine-1 residues occurring within 72 hours at ambient temperature, rendering proper cold-chain logistics non-negotiable.
Reconstitution at pH >8.0 accelerates deamidation and reduces receptor binding by 20–40% within 48 hours. The optimal protocol uses sterile water or PBS at pH 7.0–7.4 with gentle swirling, never vortexing.
Aliquoting reconstituted VIP into single-use portions stored at −80°C prevents the 15% per-cycle activity loss caused by repeated freeze-thaw, preserving full peptide function for up to six months.
The best VIP supplier provides HPLC chromatograms, mass spectrometry confirming 3326.7 Da molecular weight, and bioactivity data demonstrating EC50 values in the 1–10 nM range. Absent these, purity claims are unverifiable.

realpeptides.co

Research context

Read sources and limitations before applying a claim.

Clinical Evidence: What the Human Trials Actually Show

Human evidence for vasoactive intestinal peptide spans respiratory failure trials, chronic lung disease studies, CIRS cohorts, and observational biomarker data — a broader clinical evidence base than most peptides in current research. The data tell a complex and editorially honest story: large trials that missed primary endpoints alongside smaller trials with clear positive signals, and route of administration emerging as a variable that may matter more than the molecule itself.

Source: peptidefox.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

A Global Healing Tool Emerges

Clinical Evidence: What the Human Trials Actually Show

Peptide Therapy Guide Editorial Team

VIP (Vasoactive Intestinal Peptide) Dosing, Need to Know Information, Safety, Stacks, Dosing Calculator and more!

VIP (Vasoactive Intestinal Peptide) Protocol — Complete Dosing & Administration Guide

VIP (Vasoactive Intestinal Peptide) vs PACAP-38 — Peptide Comparison

PACAP-38 vs VIP (Vasoactive Intestinal Peptide) — Peptide Comparison